MSK Researchers Develop Targeted Test for Mutations in Both Rare and Common Cancers

Anne Li                                                                                     September 16th, 2017                            anne2001.li@gmail.com


Building on our rich history of innovation, genome scientists, bioinformaticians and molecular pathologists at Memorial Sloan Kettering Cancer Center have developed a targeted tumor sequencing test, Integrated Mutation Profiling of Actionable Cancer Targets(MSK-IMPAC), to detect gene mutations and other critical genetic aberrations in both rare and common cancers. Until now, genomic testing of tumors has been routine practice only for patients with certain solid tumors, such as melanoma, lung, and colon cancer.
See origin article at: https://www.mskcc.org/msk-impact

Post a comment